ResultsIQ

ResultsIQ › Latest results › Hikal Limited

Hikal Limited Q1 FY26 results deck summary

NSE: HIKAL · BSE: 524735

Results deck of 7 Aug 2025, summarised by AI from the filing.

Q1 FY26 consolidated revenue ₹380 cr and EBITDA ₹25 cr, impacted by US FDA OAI; management reiterates FY26 guidance.

Key takeaways

  1. Q1 FY26 result Consolidated revenue ₹380 cr (Q1 FY25: ₹407 cr, -6.5%) and EBITDA ₹25 cr (Q1 FY25: ₹58 cr, -57.4%)
  2. Guidance Management reiterates FY26 guidance, expecting pharmaceutical offtake recovery in H2 and meaningful recovery in Q3-Q4
  3. Change US FDA OAI on 22nd May led to temporary deferment of pharmaceutical offtake across generic and CDMO business
  4. Driver Recovery expected from increased demand visibility, improved capacity utilization, and new product commercialization
  5. Risk Crop protection faces persistent global overcapacity and pricing pressure from lower priced Chinese competition

Original filing on BSE

Hikal Limited Q1 FY27 results

As filed: Revenue ₹403 cr (+6% year on year), EBITDA ₹37.0 cr (+48% year on year), PAT −₹7.4 cr, EBITDA margin 9.2% (+261 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹519 cr (−6% year on year), EBITDA ₹105 cr (−14% year on year), PAT ₹14.4 cr (−19% year on year), EBITDA margin 20.3% (−199 bps). Score 30 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit before exceptional items growth was in line with it. EBITDA margin fell 199 bps year on year. Other income 80% of PBT. Tax rate -73%. Share price after the results: −2.9% in 29 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹494 cr (+10% year on year), EBITDA ₹82.7 cr (+15% year on year), PAT −₹5.9 cr (+20% year on year), EBITDA margin 16.7% (+66 bps). Score 75 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was in line with it. EBITDA margin rose 66 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −9.6% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹319 cr (−30% year on year), EBITDA ₹7.0 cr (−91% year on year), PAT −₹35.0 cr (−294% year on year), EBITDA margin 2.2% (−1,000 bps). Score 5 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 16% from last quarter. Share price after the results: +5.1% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹380 cr (−7% year on year), EBITDA ₹25.0 cr (−57% year on year), PAT −₹22.0 cr (−300% year on year), EBITDA margin 6.6% (−767 bps). Score 12 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 767 bps year on year. Revenue fell 31% from last quarter. Share price after the results: −14.8% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹552 cr (+7% year on year), EBITDA ₹123 cr (+31% year on year), PAT ₹50.0 cr (+47% year on year), EBITDA margin 22.3% (+399 bps). Score 86 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 399 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −7.8% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹448 cr (0% year on year), EBITDA ₹72.0 cr (+11% year on year), PAT ₹17.0 cr (+6% year on year), EBITDA margin 16.1% (+156 bps). Score 51 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 156 bps year on year. Profit fell 6% from last quarter.
  • Q2 FY25: Revenue ₹453 cr (+4% year on year), EBITDA ₹76.0 cr (+31% year on year), PAT ₹18.0 cr (+38% year on year), EBITDA margin 16.8% (+344 bps). Score 66 of 100, Above trend. EBITDA margin rose 344 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Hikal Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.